Literature DB >> 19581794

Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.

Susan A McCloskey1, Wainwright Jaggernauth, Nestor R Rigual, Wesley L Hicks, Saurin R Popat, Maureen Sullivan, Terry L Mashtare, Mohamed K Khan, Thom R Loree, Anurag K Singh.   

Abstract

PURPOSE: To determine whether baseline hemoglobin level and radiation treatment interruptions predict for loco-regional failure after intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for definitive treatment of squamous cell carcinoma of the head and neck (SCCHN).
METHODS: This retrospective review identified 78 consecutive patients treated with definitive concurrent chemoradiation for SCCHN. Patients were treated with IMRT to 70 Gy in 35 daily fractions to the high-dose target volume and 56 Gy to the elective target volume.
RESULTS: Median age of the cohort was 62 (37-81). Median follow-up was 12 months. Tumor sites included: oropharynx (54%), larynx (36%), oral cavity (5%), and hypopharynx (5%). Fifteen of 78 patients (19%) experienced loco-regional failure. These included: 6 primary site failures, 5 regional failures, and 4 failures in both the primary site and regional lymph nodes. All but one failure occurred in the high-dose target volume. Only duration of radiation treatment and baseline hemoglobin levels were significant predictors of local control. Loco-regional failure occurred in 6 of 13 patients (46%) with radiation treatment interruptions (>1 week) versus 9 of 65 patients (14%) completing radiation therapy without interruption (P = 0.0148). Loco-regional failure occurred in 7 of 19 patients (37%) whose pretreatment hemoglobin level was <12 g/dL compared with 8 of 59 patients (14%) with hemoglobin levels > or = 12 (P = 0.042).
CONCLUSION: Overall radiation treatment time and pretreatment hemoglobin level were significant predictors for loco-regional failure after definitive concurrent chemotherapy and IMRT for SCCHN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581794     DOI: 10.1097/COC.0b013e3181967dd0

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  27 in total

1.  Predictors of cancer-related pain improvement over time.

Authors:  Hsiao-Lan Wang; Kurt Kroenke; Jingwei Wu; Wanzhu Tu; Dale Theobald; Susan M Rawl
Journal:  Psychosom Med       Date:  2012-06-28       Impact factor: 4.312

Review 2.  The effectiveness of mouthwashes in alleviating radiation-induced oral mucositis in head and neck cancer patients: a systematic review.

Authors:  Masaru Konishi; Rinus Gerardus Verdonschot; Kiichi Shimabukuro; Takashi Nakamoto; Minoru Fujita; Naoya Kakimoto
Journal:  Oral Radiol       Date:  2018-12-10       Impact factor: 1.852

3.  Patient navigation for American Indians undergoing cancer treatment: utilization and impact on care delivery in a regional healthcare center.

Authors:  B Ashleigh Guadagnolo; Amy Boylan; Michele Sargent; David Koop; Deb Brunette; Shalini Kanekar; Vanessa Shortbull; Kevin Molloy; Daniel G Petereit
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

4.  Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.

Authors:  Mary E Platek; Susan A McCloskey; Myra Cruz; Mark S Burke; Mary E Reid; Gregory E Wilding; Nestor R Rigual; Saurin R Popat; Thom R Loree; Vishal Gupta; Graham W Warren; Maureen Sullivan; Wesley L Hicks; Anurag K Singh
Journal:  Head Neck       Date:  2012-05-22       Impact factor: 3.147

5.  Radiation therapy is well tolerated and produces excellent control rates in elderly patients with locally advanced head and neck cancers.

Authors:  Omar K Jilani; Prabhsimranjot Singh; A Gabriella Wernicke; David I Kutler; William Kuhel; Paul Christos; Dattatreyudu Nori; Albert Sabbas; Ks Clifford Chao; Bhupesh Parashar
Journal:  J Geriatr Oncol       Date:  2012-10       Impact factor: 3.599

6.  Topical Esomeprazole Mitigates Radiation-Induced Dermal Inflammation and Fibrosis.

Authors:  Ngoc Pham; Michelle S Ludwig; Min Wang; Afshin Ebrahimpour; Mark D Bonnen; Abdul Hafeez Diwan; Soo Jung Kim; Jason Bryan; Jared M Newton; Andrew G Sikora; Donald T Donovan; Vlad Sandulache; Yohannes T Ghebre
Journal:  Radiat Res       Date:  2019-08-15       Impact factor: 2.841

7.  Pretreatment weight status and weight loss among head and neck cancer patients receiving definitive concurrent chemoradiation therapy: implications for nutrition integrated treatment pathways.

Authors:  Mary E Platek; Elizabeth Myrick; Susan A McCloskey; Vishal Gupta; Mary E Reid; Gregory E Wilding; David Cohan; Hassan Arshad; Nestor R Rigual; Wesley L Hicks; Maureen Sullivan; Graham W Warren; Anurag K Singh
Journal:  Support Care Cancer       Date:  2013-06-07       Impact factor: 3.603

Review 8.  Metrics for evaluating patient navigation during cancer diagnosis and treatment: crafting a policy-relevant research agenda for patient navigation in cancer care.

Authors:  B Ashleigh Guadagnolo; Daniel Dohan; Peter Raich
Journal:  Cancer       Date:  2011-08       Impact factor: 6.860

9.  Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy.

Authors:  Mary E Platek; Mary E Reid; Gregory E Wilding; Wainwright Jaggernauth; Nestor R Rigual; Wesley L Hicks; Saurin R Popat; Graham W Warren; Maureen Sullivan; Wade L Thorstad; Mohamed K Khan; Thom R Loree; Anurag K Singh
Journal:  Head Neck       Date:  2010-12-15       Impact factor: 3.147

10.  Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation.

Authors:  Alexis J Platek; Vijayvel Jayaprakash; Mihai Merzianu; Mary E Platek; David M Cohan; Wesley L Hicks; Sathiya P Marimuthu; Timothy B Winslow; Vishal Gupta; Hassan Arshad; Moni A Kuriakose; Shiva Dibaj; James R Marshall; Mary E Reid; Graham W Warren; Anurag K Singh
Journal:  Laryngoscope       Date:  2016-06-27       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.